Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 4/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL443253 | 0.77 | PAOX (0.34) | SIGMAR1KDM4EALDH1A1TDP1 | |
| SCHEMBL10000708 | 0.77 | PAOX (0.34) | SIGMAR1KDM4EALDH1A1TDP1 | |
| SCHEMBL19361712 | 0.74 | DAO (0.35) | DAOMAOBSIGMAR1KDM4EALDH1A1 | |
| SCHEMBL28132579 | 0.73 | — | — | |
| SCHEMBL5294936 | 0.73 | — | — | |
| SCHEMBL17482092 | 0.73 | SLC6A9 (0.36) | — | |
| SCHEMBL10157511 | 0.72 | SMN1; SMN2 (0.34) | DAOMAOBSIGMAR1KDM4EALDH1A1 | |
| SCHEMBL3933419 | 0.72 | DAO (0.38) | DAOMAOBSIGMAR1KDM4EALDH1A1 | |
| SCHEMBL18269523 | 0.72 | RAB9A (0.41) | SIGMAR1 | |
| SCHEMBL15831762 | 0.72 | MEN1 (0.35) | ALDH1A1DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120029177-A1 | HETEROCYCLE-AMINO ACID DERIVATIVES FOR TARGETING CANCER TISSUE AND RADIOACTIVE OR NON-RADIOACTIVE LABELED COMPOUNDS THEREOF | SNU R&DB FOUNDATION (KR) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029177-A1 | HETEROCYCLE-AMINO ACID DERIVATIVES FOR TARGETING CANCER TISSUE AND RADIOACTIVE OR NON-RADIOACTIVE LABELED COMPOUNDS THEREOF | DDC, AAAS, DNPEP | DAO 44/4885MAOB 4614/4885SIGMAR1 1198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.